These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 32119602

  • 1. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.
    Gönüllü E, Soysal A, Yıldız I, Aydemir G, Tunç T, Karaböcüoğlu M.
    Hum Vaccin Immunother; 2020 Oct 02; 16(10):2504-2508. PubMed ID: 32119602
    [Abstract] [Full Text] [Related]

  • 2. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D, Givon-Lavi N, Ben-Shimol S, Ziv JB, Dagan R.
    Vaccine; 2015 Aug 26; 33(36):4623-9. PubMed ID: 26116251
    [Abstract] [Full Text] [Related]

  • 3. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of acute otitis media, recurrent otitis media and tympanostomy tube insertion in children after its implementation into the national immunization program in Turkey.
    Soysal A, Gönüllü E, Yıldız I, Aydemir G, Tunç T, Fırat Y, Erdamar B, Karaböcüoğlu M.
    Hum Vaccin Immunother; 2020 Aug 26; 16(2):445-451. PubMed ID: 31424317
    [Abstract] [Full Text] [Related]

  • 4. A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada.
    Vadlamudi NK, Patrick DM, Rose C, Sadatsafavi M, Hoang L, Marra F.
    Vaccine; 2022 Feb 11; 40(7):1047-1053. PubMed ID: 35012778
    [Abstract] [Full Text] [Related]

  • 5. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
    Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, Craiu I, Zenkhri F, Dubos F, Guen CG, Launay E, Martinot A, Cohen R.
    Clin Infect Dis; 2014 Apr 11; 58(7):918-24. PubMed ID: 24532543
    [Abstract] [Full Text] [Related]

  • 6. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.
    Berglund A, Ekelund M, Fletcher MA, Nyman L.
    PLoS One; 2014 Apr 11; 9(11):e112211. PubMed ID: 25379659
    [Abstract] [Full Text] [Related]

  • 7. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
    Liapikou A, Konstantinidis A, Kossyvaki V, Skiadas J, Menegas D, Méndez C, Beavon R, Begier E, Gessner BD, Milionis H, Tsimihodimos V, Baxevanos G, Argiriadou T, Terrovitou C, Toumbis M, EGNATIA Study Group.
    Hum Vaccin Immunother; 2022 Nov 30; 18(5):2079923. PubMed ID: 35703733
    [Abstract] [Full Text] [Related]

  • 8. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
    Meder KN, Jayasinghe S, Beard F, Dey A, Kirk M, Cook H, Strachan J, Sintchenko V, Smith H, Giele C, Howden B, Krause V, Mcintyre P.
    Clin Infect Dis; 2020 Jun 10; 70(12):2607-2615. PubMed ID: 31388670
    [Abstract] [Full Text] [Related]

  • 9. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
    Takeuchi N, Naito S, Ohkusu M, Abe K, Shizuno K, Takahashi Y, Omata Y, Nakazawa T, Takeshita K, Hishiki H, Hoshino T, Sato Y, Ishiwada N.
    Epidemiol Infect; 2020 Apr 17; 148():e91. PubMed ID: 32299523
    [Abstract] [Full Text] [Related]

  • 10. Pneumococcal conjugate vaccines decrease community-acquired alveolar pneumonia with and without pleural effusion in children <60 months in Southern Israel, 2002-2016.
    Triadou D, Givon-Lavi N, Greenberg D, Ben-Shimol S.
    Infect Dis (Lond); 2020 Mar 17; 52(3):186-195. PubMed ID: 31774020
    [Abstract] [Full Text] [Related]

  • 11. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine.
    Hsiao A, Hansen J, Timbol J, Lewis N, Isturiz R, Alexander-Parrish R, McLaughlin JM, Gessner BD, Klein NP.
    JAMA Netw Open; 2022 Mar 01; 5(3):e221111. PubMed ID: 35302634
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study.
    Zhang T, Zhang J, Shao X, Feng S, Xu X, Zheng B, Liu C, Dai Z, Jiang Q, Gessner BD, Chen Q, Zhu J, Luan L, Tian J, Zhao G.
    Vaccine; 2021 Jul 30; 39(33):4620-4627. PubMed ID: 34253417
    [Abstract] [Full Text] [Related]

  • 13. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.
    van Deursen AMM, Schurink-Van't Klooster TM, Man WH, van de Kassteele J, van Gageldonk-Lafeber AB, Bruijning-Verhagen PCJL, de Melker HE, Sanders EAM, Knol MJ.
    Vaccine; 2017 Dec 18; 35(51):7107-7113. PubMed ID: 29146381
    [Abstract] [Full Text] [Related]

  • 14. Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children.
    Ouldali N, Levy C, Minodier P, Morin L, Biscardi S, Aurel M, Dubos F, Dommergues MA, Mezgueldi E, Levieux K, Madhi F, Hees L, Craiu I, Gras Le Guen C, Launay E, Zenkhri F, Lorrot M, Gillet Y, Béchet S, Hau I, Martinot A, Varon E, Angoulvant F, Cohen R.
    JAMA Pediatr; 2019 Apr 01; 173(4):362-370. PubMed ID: 30715140
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study.
    Tian J, Zheng B, Yang L, Guan Y, Xu C, Wang W.
    Vaccine; 2023 Sep 22; 41(41):5979-5986. PubMed ID: 37620204
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.
    Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, Slack M, George R, Lim WS.
    Eur Respir J; 2015 Jun 22; 45(6):1632-41. PubMed ID: 25792633
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.
    Clin Ther; 2013 Feb 22; 35(2):119-34. PubMed ID: 23312274
    [Abstract] [Full Text] [Related]

  • 19. Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina.
    López EL, Glatstein E, Ezcurra GC, Iacono M, Teplitz E, Garnero AV, Lazzarini DL, Vázquez M, Contrini MM.
    J Pediatric Infect Dis Soc; 2018 Feb 19; 7(1):30-35. PubMed ID: 28339727
    [Abstract] [Full Text] [Related]

  • 20. [Effect of the Pneumococcal Conjugated Vaccines on Burden of all Cause Pneumonia, Bacterial Pneumonia and Empyema in Children].
    Tsakir C, Özdemir H, Arga G, Konca HK, Çakmak Taşkın E, Öcal D, Çiftçi E, İnce E.
    Mikrobiyol Bul; 2022 Jul 19; 56(3):466-479. PubMed ID: 35960238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.